Pancreas Preservation With Viaspan, Celsior, and Custodiol Solutions: An Initial Experience

• Published in: Transplantation proceedings Vol. 48; no. 9; pp. 3040 - 3042
• Main Authors: Montiel-Casado, M.C, Pérez-Daga, J.A, Blanco-Elena, J.A, Aranda-Narváez, J.M, Sánchez-Pérez, B, Cabello-Díaz, M, Ruiz-Esteban, P, León-Díaz, F.J, Gutiérrez-de la Fuente, C, Santoyo-Santoyo, J
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2016
• Subjects: Adenosine - pharmacology; Adult; Allopurinol - pharmacology; Blood Glucose - metabolism; C-Peptide - metabolism; Cold Ischemia; Disaccharides - pharmacology; Electrolytes - pharmacology; Female; Glucose - pharmacology; Glutamates - pharmacology; Glutathione - pharmacology; Graft Survival - drug effects; Histidine - pharmacology; Humans; Insulin - pharmacology; Male; Mannitol - pharmacology; Organ Preservation - methods; Organ Preservation Solutions - pharmacology; Pancreas - drug effects; Pancreas - physiology; Pancreas Transplantation - methods; Pancreas Transplantation - mortality; Potassium Chloride - pharmacology; Procaine - pharmacology; Prospective Studies; Raffinose - pharmacology; Retrospective Studies; Surgery; Tissue Donors - statistics & numerical data
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2016.07.042

Abstract Background There is still controversy about which preservation solution in pancreas transplantation could be the best. The aim of this study was to analyze our initial experience with Custodiol solution (CuS) compared with Viaspan solution (VS) and Celsior solution (CS) in pancreas transplantation. Methods A retrospective study included 94 consecutive pancreatic transplants, from 2007 until 2015. We compared 3 groups, depending on preservation solution: Viaspan (n = 41), Celsior (n = 40), or Custodiol (n = 13). The primary end point was patient and pancreas survival at 1 year after pancreas transplantation. Results The recipient and donor characteristics were similar except in cold ischemia time; it was higher with Celsior. No differences were found in postoperative complications and pancreas graft function at 3 months, 6 months, and 1 year (glucose, HbA1c, C-peptide, creatinine). The pancreas and patient survival at 1 year was comparable (pancreas survival: VS, 80%; CS, 90%; CuS, 92%; log-rank, 0.875; and patient survival: VS, 92%; CS, 97%; CuS, 100%; log-rank, 0.9). Conclusions In our institution, the Custodiol solution in pancreas transplantation presented similar outcomes in terms of postoperative complications, pancreas graft function, and 1-year survival.